blob: 139b72676a382bf9bb6d04ea543f7fa5a044c070 (
plain)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
|
# CorMedix inc. - NASDAQ:CRMD
Story parrallel to suganmadex introduction
Taurolock & Taurolidine
Solving CRBST (catherer blood stream infection)
CRMD instead of using Citrate develloped their own solution.
Pairing Taurolidine with heparin making DefenCath
DefenCath FDA approved in Nov 2023
Target: Hospitals & dyalisis clinics
Total Market potential more or less ~170,000 patient
now around ~3000 patient
already signed contracts for 70% TAM (?)
looking at end 2027$
~250$ per vial
CRBST cost around 63,000$ per case, nothing compared to 250$
NTAP end Nov 2026
|
